Epitel develops the REMI Remote EEG Monitoring System, a wireless, wearable EEG platform designed to enable extended-duration brain monitoring at home for days to weeks. The REMI portfolio has received five U.S. FDA 510(k) clearances across its wireless EEG monitoring and AI-driven event detection technologies. REMI Vigilenz AI analyzes REMI EEG to flag potential seizures and is cleared for use in patients aged six and older, while the overall platform is cleared for patients as young as one year. Epitel is initially focused on seizure detection and diagnosis and cites gaps in access—noting 9.2 million Americans experience seizures annually while many lack EEG access. The company says its technology aims to improve clinician workflow by accelerating capture of objective seizure evidence and to broaden access to neurological care outside traditional hospital settings. With the recently closed Series B, Epitel plans to expand its commercial infrastructure and field team to accelerate adoption and market penetration.

Total raised

$56M

Funding rounds

12

Latest round

Series B

Latest activity

Jul 2026